| ‘Genotype/immunotype’correlations in resected NSCLC PK Paik, MD Hellmann Annals of Oncology 28 (1), 7-8, 2017 | | 2017 |
| " INTENTION-TO-TREAT" OUTCOMES OF SEQUENTIAL PATIENTS WITH STAGE IIIA LUNG ADENOCARCINOMAS TREATED WITH NEOADJUVANT CHEMOTHERAPY WITH INTENT OF SURGICAL RESECTION MD Hellmann, JE Chaft, PD Hilden, VW Rusch, MG Kris JOURNAL OF THORACIC ONCOLOGY 8, S1147-S1147, 2013 | | 2013 |
| 1054P Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer A Elkrief, A Bowman, H Rizvi, M Hellmann, GJ Riely, AJ Schoenfeld, ... Annals of Oncology 33, S1037, 2022 | | 2022 |
| 1075TiP MEDI1191, a novel IL-12 mRNA therapy for intratumoral (IT) injection for advanced solid tumours T Marron, V Subbiah, O Hamid, S Goel, MD Hellmann, BA Carneiro, ... Annals of Oncology 31, S730, 2020 | 1 | 2020 |
| 122MO Nivolumab (NIVO)+ ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets … M Reck, TE Ciuleanu, A Pluzanski, JS Lee, RB Caro, H Linardou, ... Annals of Oncology 32, S1430-S1431, 2021 | 7 | 2021 |
| 1264P Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC … S Peters, NA Rizvi, M Kuziora, Z Lai, Y Shrestha, A Dey, JC Barrett, ... Annals of Oncology 32, S989-S990, 2021 | | 2021 |
| 274 Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L) 1 blockade in patients with advanced non-small cell lung cancer M Ascierto, M Hellmann, N Standifer, S Wu, H Si, C Morehouse, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | | 2020 |
| 3-Year Overall Survival for Patients with Advanced NSCLC Treated with Pembrolizumab MD Hellmann, NB Leighl, R Hui, E Carcereny, E Felip, MJ Ahn, JP Eder, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 13, 60-61, 2017 | | 2017 |
| 30 Immunotherapy in advanced NSCLC—from the ‘tsunami’of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the … F de Marinis, F Ciardiello, P Baas, L Crinò, G Giaccone, F Grossi, ... ESMO open 3 (4), e000298, 2018 | 10 | 2018 |
| 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses SN Gettinger, MD Hellmann, FA Shepherd, SJ Antonia, J Brahmer, ... European Journal of Cancer 3 (51), S632, 2015 | 10 | 2015 |
| 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC) MD Hellmann, N Rizvi, SN Gettinger, J Goldman, LQ Chow, R Juergens, ... European Journal of Cancer 3 (51), S632-S633, 2015 | 6 | 2015 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| 327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma J Zhang, J Caushi, G Oliveira, B Zhang, Z Ji, J Naidoo, K Marrone, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| 33LBA efficacy and safety of pembrolizumab (Pembro; MK-3475) for patients (Pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001 JC Soria, O Flatten, L Horn, E Felip, L Gandhi, R Hui, M Hellmann, ... European Journal of Cancer 3 (51), S726-S727, 2015 | 15 | 2015 |
| 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. E Felip, MD Hellmann, R Hui, E Carcereny, NB Leighl, MJ Ahn, JP Eder, ... Journal of Clinical Oncology 36 (15_suppl), 9030-9030, 2018 | 15 | 2018 |
| 457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC) M Gutierrez, WS Lam, M Hellmann, M Gubens, C Aggarwal, DSW Tan, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 5 | 2021 |
| 459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC M Hellmann, B Cho, R Juergens, Y Cheng, G de Castro, M Erman, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A488-A488, 2021 | | 2021 |
| 459P Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001 MJ Ahn, L Gandhi, O Hamid, MD Hellmann, EB Garon, SS Ramalingam, ... Annals of Oncology 26, ix125, 2015 | 18 | 2015 |
| 4O Nivolumab (NIVO)+ ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and … SS Ramalingam, D Balli, TE Ciuleanu, A Pluzanski, JS Lee, M Schenker, ... Annals of Oncology 32, S1375-S1376, 2021 | 15 | 2021 |
| 503 Pneumonitis with anti-PD-1/PD-L1 therapy J Naidoo, J Cunningham, KM Woo, MD Hellmann, MA Postow, AE Drilon, ... European Journal of Cancer 3 (51), S103, 2015 | 8 | 2015 |
